Company Profile

Xemed LLC (AKA: Xemed)
Profile last edited on: 5/27/20      CAGE: 488D4      UEI: YJ8MJGAAWGM7

Business Identifier: Inhaled diagnostic agents capable of changing respiratory diseases managment
Year Founded
2004
First Award
2004
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

16 Strafford Avenue
Durham, NH 03824
   (603) 868-1888
   info@emed.com
   www.xemed.com
Location: Single
Congr. District: 01
County: Strafford

Public Profile

Xemed is a product focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gas MRI. The firm is set up to partner with clinical researchers, the pharmaceutical industry, and NIH to advance pulmonary functional imaging through the regulatory approval process towards commercialization. Xemed collaborates with academic partners throughout its MagniXene® Imaging Network to refine its technologies and to assess safety and efficacy of pulmonary functional imaging applications in disease management and drug development X, Pulmonary functional imaging with MagniXene® can provide a foundation for a new era of personalized care in respiratory diseases. A new category of minimally-invasive procedures and conformal therapies will be able to benefit from image guidance from 3D maps of lung functional microstructure. With a focus is on COPD, asthma, and cancer, the judgment of management is that MagniXene® may play many roles in patient care: evaluating antibiotic wash-out treatment in children with cystic fibrosis exacerbations, evaluating impairment of oxygen uptake due to pulmonary emboli pre- and post-endarterectomy, and providing early signs of bronchiolitis obliterans in lung transplant tissue rejection

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 2 AF $1,147,291
Project Title: Compact external-cavity DPAL pump system with atomic wavelength stability
2017 2 NIH $1,486,280
Project Title: Assessment of Lung Function in Neonates and Infants
2015 2 DOE $2,149,071
Project Title: Polarized 3He Gas Circulating Technologies for Neutron Analyzers
2015 2 DOE $1,149,194
Project Title: Polarized 3He Pressurization Loop for an Electron Beam Target
2015 2 NIH $1,848,415
Project Title: Single-Session Bronchial Thermoplasty for Severe Asthmatics Guided by Hxe Mri

Key People / Management

  F William Hersman -- President/CEO

  Steve Bryn -- Director, Information Technology

  Jan H Distelbrink -- Senior Scientist, Director of MagniXene™ Polarization Systems

  Iulian C Ruset -- Research Scientist, Director of Imaging Applications

  David W Watt -- Director, MagniLium Division